Los Angeles Capital Management LLC Trims Position in Jazz Pharmaceuticals PLC $JAZZ

Los Angeles Capital Management LLC trimmed its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 11.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 109,908 shares of the specialty pharmaceutical company’s stock after selling 14,790 shares during the period. Los Angeles Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $18,684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Vestal Point Capital LP purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $127,344,000. Goldentree Asset Management LP purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $149,597,000. Bank of New York Mellon Corp raised its holdings in shares of Jazz Pharmaceuticals by 160.2% in the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after buying an additional 715,361 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 592.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after buying an additional 373,383 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 62.1% in the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after buying an additional 304,463 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JAZZ shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Sanford C. Bernstein assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, May 21st. They set a “market perform” rating and a $229.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and set a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Wells Fargo & Company boosted their price target on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Barclays boosted their price target on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $242.65.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the transaction, the director directly owned 18,449 shares in the company, valued at approximately $4,446,209. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 10,741 shares of company stock worth $2,287,143. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $238.57 on Monday. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The firm’s 50-day moving average is $213.11 and its two-hundred day moving average is $187.01. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The firm has a market capitalization of $14.97 billion, a P/E ratio of -11,922.54, a PEG ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.